Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.

The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...

In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...